Search Results Showing 1 of 1 search results for: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers Status Recruiting Condition Neoplasms Phase Phase 1 INTERVENTION Drug: CC-95251, Drug: Rituximab, Drug: Cetuximab Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 1 of 1